The aim of this clinical trial is to analyze the negative predictive capacity and safety of risk-stratified direct drug provocation tests for patients with self-reported penicillin allergies. Patients reporting immediate or delayed penicillin allergies and defined as low-risk by the PEN-FAST score will receive drug provocation tests without prior skin testing.
Adult outpatients or inpatients with a penicillin allergy label
Willing and able to give consent.
PEN-FAST score of 0-2 points
Age <18 years
Concurrent immunosuppressive therapy with 20 mg of prednisolone per day or steroid equivalent
Concurrent antihistamine therapy
Pregnancy
Deniz Göcebe
Lead sponsor
University Hospital Heidelberg
Sponsor institution